Thomas Korff1, Karin Aufgebauer, Markus Hecker. 1. University Hospital Heidelberg, Institute of Physiology and Pathophysiology, Division of Cardiovascular Physiology, Im Neuenheimer Feld 326, 69120 Heidelberg, Germany.
Abstract
BACKGROUND: CD40 is a costimulatory molecule that acts as a central mediator of various immune responses, including those involved in the progression of atherosclerosis. Correspondent to its function, CD40 is present not only on many immune cells, such as antigen-presenting cells and T cells, but also on nonimmune cells, such as endothelial cells. METHODS AND RESULTS: Ex vivo analyses in mice revealed that CD40 is strongly expressed in distinct venous and capillary but not arterial endothelial cell populations. Therefore, we analyzed to what extent determinants of an arterial environment control CD40 expression in these cells. In vitro studies indicated that the presence of smooth muscle cells or exposure to cyclic stretch significantly downregulates CD40 expression in human endothelial cells. Interestingly, endothelial cells cocultured with smooth muscle cells upregulated CD40 expression in response to cyclic stretch through a transforming growth factor-beta1/activin-receptor-like kinase-1 (Alk-1)-dependent mechanism. To corroborate that this mechanism also operates in arteries in vivo, we analyzed the expression of Alk-1 and CD40 at atherosclerosis-prone sites of the mouse aorta that also appear to be exposed to increased stretch. In wild-type mice, both Alk-1 and CD40 revealed a comparably heterogeneous expression pattern along the aortic arch that matched those sites in low-density lipoprotein-receptor-deficient mice where atherosclerotic lesions develop. CONCLUSIONS: Cyclic stretch thus increases the abundance of CD40 in endothelial cells through transforming growth factor-beta1/Alk-1 signaling. This mechanism in turn may be responsible for the heterogeneous expression of CD40 at arterial bifurcations or curvatures and would support a site-specific proinflammatory response that is typical for the early phase of atherosclerosis.
BACKGROUND:CD40 is a costimulatory molecule that acts as a central mediator of various immune responses, including those involved in the progression of atherosclerosis. Correspondent to its function, CD40 is present not only on many immune cells, such as antigen-presenting cells and T cells, but also on nonimmune cells, such as endothelial cells. METHODS AND RESULTS: Ex vivo analyses in mice revealed that CD40 is strongly expressed in distinct venous and capillary but not arterial endothelial cell populations. Therefore, we analyzed to what extent determinants of an arterial environment control CD40 expression in these cells. In vitro studies indicated that the presence of smooth muscle cells or exposure to cyclic stretch significantly downregulates CD40 expression in human endothelial cells. Interestingly, endothelial cells cocultured with smooth muscle cells upregulated CD40 expression in response to cyclic stretch through a transforming growth factor-beta1/activin-receptor-like kinase-1 (Alk-1)-dependent mechanism. To corroborate that this mechanism also operates in arteries in vivo, we analyzed the expression of Alk-1 and CD40 at atherosclerosis-prone sites of the mouse aorta that also appear to be exposed to increased stretch. In wild-type mice, both Alk-1 and CD40 revealed a comparably heterogeneous expression pattern along the aortic arch that matched those sites in low-density lipoprotein-receptor-deficient mice where atherosclerotic lesions develop. CONCLUSIONS: Cyclic stretch thus increases the abundance of CD40 in endothelial cells through transforming growth factor-beta1/Alk-1 signaling. This mechanism in turn may be responsible for the heterogeneous expression of CD40 at arterial bifurcations or curvatures and would support a site-specific proinflammatory response that is typical for the early phase of atherosclerosis.
Authors: Alexander H Licht; Tobias Nübel; Anja Feldner; Nathalie Jurisch-Yaksi; Marco Marcello; Elena Demicheva; Jun-Hao Hu; Bettina Hartenstein; Hellmut G Augustin; Markus Hecker; Peter Angel; Thomas Korff; Marina Schorpp-Kistner Journal: J Clin Invest Date: 2010-06-14 Impact factor: 14.808
Authors: Lucia M Mokres; Kakoli Parai; Anne Hilgendorff; Robert Ertsey; Cristina M Alvira; Marlene Rabinovitch; Richard D Bland Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-10-23 Impact factor: 5.464
Authors: Yu-Tzu Tai; Ender Soydan; Weihua Song; Mariateresa Fulciniti; Kihyun Kim; Fangxin Hong; Xian-Feng Li; Peter Burger; Matthew J Rumizen; Sabikun Nahar; Klaus Podar; Teru Hideshima; Nikhil C Munshi; Giovanni Tonon; Ruben D Carrasco; Daniel E H Afar; Kenneth C Anderson Journal: Blood Date: 2009-02-04 Impact factor: 22.113
Authors: J Deweirdt; T Ducret; J-F Quignard; V Freund-Michel; S Lacomme; E Gontier; B Muller; R Marthan; C Guibert; I Baudrimont Journal: Cardiovasc Toxicol Date: 2021-09-15 Impact factor: 3.231
Authors: Gregorio Ragazzini; Jessica Guerzoni; Andrea Mescola; Domenico Di Rosa; Lorenzo Corsi; Andrea Alessandrini Journal: Ann Biomed Eng Date: 2021-03-16 Impact factor: 3.934